Phase 2 N=15 Randomized Quadruple-blind Other

Anti-Platelets in Chronic Obstructive Pulmonary Disease

COPD · Emphysema · Emphysema or COPD

Bottom Line

View on ClinicalTrials.gov: NCT05567562 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2026

Primary outcome: Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: dual anti-platelet therapy (Combination_product); Placebo (Drug)
Age: Adult, Older Adult · 50+ yrs
Sex: All
Sponsor: Brigham and Women's Hospital
Primary completion: Feb 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Pulmonary Microvascular Blood Volume, CV	0.89; 0.88; 0.92; 0.91; 0.81; 0.80	0.84
SECONDARY Pulmonary Microvascular Blood Volume	602.8; 595.0; 581.7; 592.9; 655.5; 600.2	0.98
SECONDARY Oxygen Saturation	95.64; 95.71; 94.9; 95.5; 97.5; 96.25	0.75

Summary

This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.

Eligibility Criteria

Inclusion Criteria - COPD Cases:

COPD (FEV1/FVC = LLN), GOLD Stage I/II/III (FEV1 >= 40%)
Current or former smoker of at least 10 pack years

Inclusion Criteria - Controls:

Normal lung function (FEV1/FVC >= 0.7, FEV1 and FVC >= LLN)
Current or former smoker of at least 10 pack years

Exclusion Criteria

Platelet count 35;
History of intracranial hemorrhage, severe GI bleed or other life-threatening bleed;
Use of blood thinner (e.g. warfarin, lovenox or novel oral anti-coagulants);
Continuous use of supplemental oxygen at home;
Regular use of an NSAID;
Daily use of oral steroids, theophylline, roflumilast, or loop diuretics;
History of organ transplant or autoimmune disease on systemic therapy (rheumatoid arthritis, lupus);
Use of a biologic medication with regular injections;
Other current lung disease (interstitial lung disease, idiopathic pulmonary fibrosis, asthma);
IV drug use within the last year;
History of lung surgery to remove part of the lung;
Known bullae or advanced destructive emphysema in more than 1/3 of the lungs;
Treatment for cancer (systemic therapy or surgical/radiation within the thorax) in the last 12 months;
Known diagnosis of pulmonary hypertension;
Known systolic heart failure (RV or LV EF < 40%);
Acute or chronic renal insufficiency (estimated glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or self-report). GFR will be calculated using the CKD-EPI equation;
Current or planned pregnancy in the next year;
Regular marijuana smoking;
Exacerbation of respiratory symptoms within the previous 6 weeks, such as that requiring hospitalization, oral prednisone or antibiotics to control symptoms, or longer and not yet returned to baseline; and
Chest, abdominal or eye surgery, or a heart attack or stroke, within the last 3 months.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05567562). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.